Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Jenscare Scientific Co. Ltd. Class H ( (HK:9877) ) is now available.
Jenscare Scientific Co., Ltd. announced its unaudited consolidated interim results for the first half of 2025, reporting a revenue of RMB13.4 million and a total income and gains of RMB25.5 million. Although the company experienced a loss for the period, the adjusted non-IFRS loss showed a slight improvement due to revenue growth and enhanced operational efficiency. The company made significant progress in its product pipeline, particularly with the LuX-Valve Plus transcatheter tricuspid valve replacement system, achieving key milestones in China, Europe, and the U.S. Jenscare is expanding its global business layout and enhancing its market influence, which is expected to contribute to its revenue and accelerate its profit targets.
More about Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd. is a company based in China that specializes in the development and commercialization of structural cardiac intervention products. The company focuses on interventional treatments for aortic, tricuspid, and mitral valve diseases, aiming to establish a diversified and high-potential product portfolio.
Average Trading Volume: 1,075,003
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.89B
See more insights into 9877 stock on TipRanks’ Stock Analysis page.